Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.66
SQNM's Cash to Debt is ranked lower than
84% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. SQNM: 0.66 )
Ranked among companies with meaningful Cash to Debt only.
SQNM' s 10-Year Cash to Debt Range
Min: 0.41  Med: 14.80 Max: No Debt
Current: 0.66
Equity to Asset -0.10
SQNM's Equity to Asset is ranked lower than
94% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SQNM: -0.10 )
Ranked among companies with meaningful Equity to Asset only.
SQNM' s 10-Year Equity to Asset Range
Min: -0.48  Med: 0.69 Max: 0.96
Current: -0.1
-0.48
0.96
F-Score: 5
Z-Score: -6.38
M-Score: -2.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -17.49
SQNM's Operating margin (%) is ranked higher than
61% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. SQNM: -17.49 )
Ranked among companies with meaningful Operating margin (%) only.
SQNM' s 10-Year Operating margin (%) Range
Min: -11450  Med: -142.98 Max: -24.12
Current: -17.49
-11450
-24.12
Net-margin (%) 20.33
SQNM's Net-margin (%) is ranked higher than
88% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. SQNM: 20.33 )
Ranked among companies with meaningful Net-margin (%) only.
SQNM' s 10-Year Net-margin (%) Range
Min: -10900  Med: -136.64 Max: 0.67
Current: 20.33
-10900
0.67
ROA (%) 22.26
SQNM's ROA (%) is ranked higher than
96% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. SQNM: 22.26 )
Ranked among companies with meaningful ROA (%) only.
SQNM' s 10-Year ROA (%) Range
Min: -92.63  Med: -50.89 Max: 0.66
Current: 22.26
-92.63
0.66
ROC (Joel Greenblatt) (%) -22.36
SQNM's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. SQNM: -22.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SQNM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -896.3  Med: -386.91 Max: -69.76
Current: -22.36
-896.3
-69.76
Revenue Growth (3Y)(%) 32.40
SQNM's Revenue Growth (3Y)(%) is ranked higher than
85% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SQNM: 32.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SQNM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -20.6  Med: -14.30 Max: 293.1
Current: 32.4
-20.6
293.1
EBITDA Growth (3Y)(%) -75.40
SQNM's EBITDA Growth (3Y)(%) is ranked lower than
98% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. SQNM: -75.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SQNM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.4  Med: -22.20 Max: 45.7
Current: -75.4
-75.4
45.7
EPS Growth (3Y)(%) -45.70
SQNM's EPS Growth (3Y)(%) is ranked lower than
90% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. SQNM: -45.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SQNM' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.3  Med: -21.45 Max: 43.7
Current: -45.7
-59.3
43.7
» SQNM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SQNM Guru Trades in Q1 2014

Jim Simons 693,351 sh (New)
» More
Q2 2014

SQNM Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q4 2014

SQNM Guru Trades in Q4 2014

Jim Simons 34,240 sh (New)
» More
Q1 2015

SQNM Guru Trades in Q1 2015

Jim Simons 89,700 sh (+161.97%)
» More
» Details

Insider Trades

Latest Guru Trades with SQNM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 10.85
SQNM's P/E(ttm) is ranked higher than
91% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. SQNM: 10.85 )
Ranked among companies with meaningful P/E(ttm) only.
SQNM' s 10-Year P/E(ttm) Range
Min: 10.77  Med: 15.45 Max: 239.38
Current: 10.85
10.77
239.38
Forward P/E 39.84
SQNM's Forward P/E is ranked lower than
72% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. SQNM: 39.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.50
SQNM's PE(NRI) is ranked higher than
72% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. SQNM: 22.50 )
Ranked among companies with meaningful PE(NRI) only.
SQNM' s 10-Year PE(NRI) Range
Min: 22.54  Med: 27.54 Max: 35.31
Current: 22.5
22.54
35.31
P/S 2.30
SQNM's P/S is ranked higher than
85% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. SQNM: 2.30 )
Ranked among companies with meaningful P/S only.
SQNM' s 10-Year P/S Range
Min: 0.99  Med: 4.81 Max: 29.2
Current: 2.3
0.99
29.2
Current Ratio 4.49
SQNM's Current Ratio is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. SQNM: 4.49 )
Ranked among companies with meaningful Current Ratio only.
SQNM' s 10-Year Current Ratio Range
Min: 1.15  Med: 3.81 Max: 26.12
Current: 4.49
1.15
26.12
Quick Ratio 4.29
SQNM's Quick Ratio is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. SQNM: 4.29 )
Ranked among companies with meaningful Quick Ratio only.
SQNM' s 10-Year Quick Ratio Range
Min: 0.94  Med: 3.40 Max: 26.03
Current: 4.29
0.94
26.03
Days Inventory 32.22
SQNM's Days Inventory is ranked higher than
83% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. SQNM: 32.22 )
Ranked among companies with meaningful Days Inventory only.
SQNM' s 10-Year Days Inventory Range
Min: 19.21  Med: 106.25 Max: 271.27
Current: 32.22
19.21
271.27
Days Sales Outstanding 18.36
SQNM's Days Sales Outstanding is ranked higher than
85% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SQNM: 18.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
SQNM' s 10-Year Days Sales Outstanding Range
Min: 7.79  Med: 57.54 Max: 182.5
Current: 18.36
7.79
182.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.48
SQNM's Price/Median PS Value is ranked higher than
87% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. SQNM: 0.48 )
Ranked among companies with meaningful Price/Median PS Value only.
SQNM' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 1.05 Max: 36.3
Current: 0.48
0.23
36.3
Earnings Yield (Greenblatt) (%) -1.04
SQNM's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SQNM: -1.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SQNM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.05  Med: 2885.20 Max: 10992.1
Current: -1.04
-1.05
10992.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QNMA.Germany,
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life sciences company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
» More Articles for SQNM

Headlines

Articles On GuruFocus.com
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
GuruFocus 5-year lows: Anworth Mortgage Asset Corporation, Contango Oil & Gas Company, Dendreon Corp Sep 29 2013 
Weekly Three-Year Low Highlights: NS, MCRL, TITN, SQNM Sep 24 2013 
5 Year Lows: Anworth Mortgage Asset Corporation, Cantago Oil & Gas Company, Sequenom and North Ameri Sep 22 2013 
Gurus Hold Five-Year Lows in Biotech, Utilities Sep 20 2013 
3.31 Mar 12 2013 
Weekly CFO Buys Highlight: PTSX, MTG, IRDM, SQNM, FNFG, LF Aug 13 2012 
Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares Aug 03 2012 
Sequenom Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sequenom Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Sequenom Announces 2015 Second Quarter Results Conference Call Jul 15 2015
Sequenom Announces 2015 Second Quarter Results Conference Call Jul 15 2015
Sequenom Laboratories Launches MaterniT™ GENOME Jul 13 2015
Sequenom Laboratories Launches MaterniT™ GENOME Jul 13 2015
SEQUENOM INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jun 25 2015
SEQUENOM INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events,... Jun 19 2015
Sequenom Welcomes Catherine J. Mackey, Ph.D., To Board Of Directors Jun 18 2015
Sequenom Welcomes Catherine J. Mackey, Ph.D., To Board Of Directors Jun 18 2015
Sequenom Comments On U.S. Court Of Appeals For The Federal Circuit Ruling On '540 Patent Jun 12 2015
Prenatal DNA test patent invalid -U.S. appeals court Jun 12 2015
SEQUENOM INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jun 11 2015
Sequenom Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes Jun 04 2015
SEQUENOM INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an... Jun 04 2015
Sequenom Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes Jun 04 2015
Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities May 27 2015
Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities May 27 2015
Sequenom, Inc. To Present At Jefferies Global Healthcare Conference May 27 2015
Sequenom, Inc. To Present At Jefferies Global Healthcare Conference May 27 2015
SEQUENOM INC Financials May 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK